ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Welcome to the ACR/ARP Abstracts Website

There are several ways to explore this site:

  1. Browse 2022 abstracts in numerical order.
  2. Browse 2022 abstracts by viewing the list of session titles.
  3. View abstracts about a certain topic by visiting the keyword index.
  4. Search this site for a specific abstract.
  5. Access the meetings archive to view abstracts from previous meetings.

ACR Convergence: Where Rheumatology Meets. November 10-14. Philadelphia, Pennsylvania

Archives

Archives

View available meetings

Search

Search

Search abstracts in detail

Download

Download

Abstracts PDFs

Recent Meetings

ACR Convergence 2022
November 10-14, 2022
Philadelphia, PA
ACR Convergence 2021
November 5-9, 2021
All Virtual

2022 Late-Breaking Abstracts

  • Abstract Number: L01
    Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study
  • Abstract Number: L02
    Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
  • Abstract Number: L03
    A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
  • Abstract Number: L04
    Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis
  • Abstract Number: L05
    Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase
  • Abstract Number: L06
    Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
  • Abstract Number: L07
    Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
  • Abstract Number: L08
    Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
  • Abstract Number: L09
    Impact on Access to Methotrexate in the Post-Roe Era
  • Abstract Number: L10
    Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
  • Abstract Number: L11
    Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial
  • Abstract Number: L12
    First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
  • Abstract Number: L13
    Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
  • Abstract Number: L14
    Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
  • Abstract Number: L15
    Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
  • Abstract Number: L16
    Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
  • Abstract Number: L17
    Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences